Skip to content

Nuvalent, Inc. NUVL Total Operating Expenses

Total Operating Expenses at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
$195.21M+192%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$445.22M+84.9%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s total operating expenses?
Nuvalent, Inc. (NUVL) reported total operating expenses of $119.41M in Q1 2026.
How has Nuvalent, Inc.'s total operating expenses changed year-over-year?
Nuvalent, Inc.'s total operating expenses increased by 25.9% year-over-year, from $94.81M to $119.41M.
What is the long-term trend for Nuvalent, Inc.'s total operating expenses?
Over 4 years (2021 to 2025), Nuvalent, Inc.'s total operating expenses has grown at a 73.4% compound annual growth rate (CAGR), from $45.82M to $414.31M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.